Anthony Welters Biography and Net Worth

Director of Gilead Sciences

Mr. Welters joined our Board in October 2020 and was appointed Lead Independent Director in May 2024. Mr. Welters is Founder, Chairman and Chief Executive Officer of CINQ Care Inc., a physician-led, community-based ambulatory care delivery system that delivers whole person care in the home, whenever possible. He is also Executive Chairman of the BlackIvy Group, an organization focused on building and growing commercial enterprises in Sub-Saharan Africa, and Chairman of Somatus Inc., a value-based kidney care company. Mr. Welters founded AmeriChoice in 1989 and, upon acquisition by UnitedHealth Group (UHG) in 2002, joined UHG as Senior Adviser to the Office of the Chief Executive Officer, Executive Vice President and Member of the Office of the Chief Executive Officer, until retiring in 2016. He currently serves on the boards of directors of Loews Corporation and the Carlyle Group. Mr. Welters previously served on the boards of directors of West Pharmaceutical Services Inc. from 1997 to 2016, and C.R. Bard Inc. from 1999 to 2017. He is Trustee Emeritus of the Morehouse School of Medicine Board of Trustees, Chairman Emeritus of the Board of New York University School of Law, Vice Chairman of the Board of New York University, a Trustee of NYU Langone Medical Center, Vice Chair of the John F. Kennedy Center for the Performing Arts and a founding member of the National Museum of African American History and Culture. 

What is Anthony Welters' net worth?: The estimated net worth of Anthony Welters is at least $1.92 million as of August 26th, 2026. Mr. Welters owns 12,894 shares of Gilead Sciences stock worth more than $1,919,401 as of August 28th. This net worth evaluation does not reflect any other investments that Mr. Welters may own. Learn More about Anthony Welters' net worth.
How do I contact Anthony Welters?: The corporate mailing address for Mr. Welters and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Anthony Welters' contact information.
Has Anthony Welters been buying or selling shares of Gilead Sciences?: During the past quarter, Anthony Welters has sold $2,675,160.00 in Gilead Sciences stock. Most recently, Anthony Welters sold 18,000 shares of the business's stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a transaction totalling $2,675,160.00. Following the completion of the sale, the director now directly owns 12,894 shares of the company's stock, valued at $1,916,306.28. Learn More on Anthony Welters' trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Jeffrey Bluestone (Director), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), Kelly Kramer (Director), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Daniel O'Day (Chairman and Chief Executive Officer), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Deborah Telman (Executive Vice President, Corporate Affairs and General Counsel), Robin Washington (CFO), Anthony Welters (Director), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 42 times. They sold a total of 613,037 shares worth more than $83,001,687.26. The most recent insider tranaction occured on August, 26th when Director Anthony Welters sold 18,000 shares worth more than $2,675,160.00. Insiders at Gilead Sciences own 0.3% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 8/26/2026.

Anthony Welters Insider Trading History at Gilead Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/26/2026	Sell	18,000	$148.62	$2,675,160.00	12,894

Anthony Welters Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $148.86

$146.01

$149.11

50 Day Range

MA: $133.81

$123.76

$148.86

2 Week Range

Now: $148.86

$108.46

$157.29

Volume

4,981,389 shs

Average Volume

6,553,708 shs

Market Capitalization

$184.58 billion

P/E Ratio

N/A

Dividend Yield

2.21%

Beta

0.32